Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A
- 1 January 2010
- journal article
- review article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 104 (11) , 931-940
Abstract
The development of inhibitors that neutralise the function of factor VIII (FVIII) is currently not only the most challenging complication associated with the treatment of haemophilia A but it also increases the disease-related morbidity as bleeding episodes do not respond to standard therapy. The main short-term goal of the treatment of inhibitor patients is to control bleeding episodes while the long-term one is to permanently eradicate the inhibitor by immune tolerance induction, particularly in the case of high-titer antibodies. Due to some in vitro studies and clinical observations, some investigators have suggested that FVIII concentrates containing von Willebrand factor (VWF) may be less immunogenic than high-purity or recombinant FVIII products. It has also been suggested that success rates for immune tolerance induction are higher when plasma-derived FVIII products are used. The currently available data from laboratory and clinical studies on the role of VWF in inhibitor development and eradication in haemophilia A is critically analysed in this review. As a result, we have not found definitive evidence supporting a role for product type on inhibitor incidence and inhibitor eradication in haemophilia A patients.Keywords
This publication has 70 references indexed in Scilit:
- Impact of polymorphisms of the major histocompatibility complex class II, interleukin‐10, tumor necrosis factor‐α and cytotoxic T‐lymphocyte antigen‐4 genes on inhibitor development in severe hemophilia AJournal of Thrombosis and Haemostasis, 2009
- Inhibitors of Factor VIII in Black Patients with HemophiliaNew England Journal of Medicine, 2009
- Haemophilia A in two unrelated females due to F8 gene inversions combined with skewed inactivation of X chromosomeThrombosis and Haemostasis, 2009
- Inhibitors in haemophilia A: current management and open issuesHaemophilia, 2007
- Inhibitor Development in Hemophiliacs: The Roles of Genetic versus Environmental FactorsSeminars in Thrombosis and Hemostasis, 2006
- The safety and efficacy of B‐domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an updateHaemophilia, 2005
- The epidemiology of inhibitors in haemophilia A: a systematic reviewHaemophilia, 2003
- Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentratesHaemophilia, 1999
- The Role of Genetics in Inhibitor FormationThrombosis and Haemostasis, 1999
- Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIIIThe Lancet, 1993